TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial. / Salazar R, et al.
Abstract LBA90 Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors(EGFRIs) in patient(pts) with RAS wildtype(wt) metastatic colorectal cancer(mCRC) -FAEISS study-. / Yamazaki N, et al.
Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens / Kang Y-K, et al.
LBA10_PR ClarlDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patinets with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
G.K. Abou-Alfa, T. Macarulla, M. Javle, et al.